BRIEF-Insys Therapeutics' NDA For Buprenorphine Sublingual Spray Accepted By FDA By: Reuters: Company News December 06, 2017 at 10:02 AM EST * FDA ACCEPTS NEW DRUG APPLICATION (NDA) FOR BUPRENORPHINE SUBLINGUAL SPRAY FROM INSYS THERAPEUTICS Read More >> Related Stocks: Insys Therapeutics Inc